XML 158 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisitions (Tables)
12 Months Ended
Dec. 31, 2019
Rave  
Acquisitions  
Schedule of Components and fair value allocation of the consideration transferred in connection with acquisitions

Consideration Transferred:

    

  

Cash paid

$

55.8

Contingent consideration

4.4

Working capital adjustment

(3.6)

Total consideration transferred

$

56.6

Allocation of Consideration Transferred:

 

  

Inventories

$

23.1

Accounts receivable

 

2.2

Other current and non current assets

 

0.8

Property, plant and equipment

 

2.1

Operating lease assets

1.0

Intangible assets:

Technology

 

17.9

Customer relationships

 

15.5

Trade name

 

1.5

Goodwill

 

6.4

Liabilities assumed

 

(13.9)

Total consideration transferred

$

56.6

2019 Acquisitions  
Acquisitions  
Schedule of consideration transferred and the respective reporting segment for each acquisition

Name of Acquisition

    

Date Acquired 

    

Segment

    

Consideration

    

Cash Consideration

Arxspan, LLC 

March 4, 2019

BSI Life Science

$

16.6

$

14.4

Ampegon PPT GmbH

March 7, 2019

 

BEST

 

2.0

 

2.0

PMOD Technologies GmbH 

July 1, 2019

 

BSI Life Science

 

8.9

 

7.9

Magnettech GmbH

October 2, 2019

 

BSI Life Science

 

9.3

 

9.3

BioVendor Instruments a.s.

November 1, 2019

 

BSI Life Science

 

1.3

 

1.3

  

 

  

$

38.1

$

34.9

2018 Acquisitions  
Acquisitions  
Schedule of consideration transferred and the respective reporting segment for each acquisition

The following tables reflect the consideration transferred and the respective reportable segment for each of the 2018 acquisitions:

    

Anasys

    

JPK

    

Mestrelab

    

Hain

    

Alicona

BSI

BSI

Segment

BSI NANO

BSI NANO

 Life Science

 Life Science

BSI NANO

Consideration Transferred:

 

  

 

  

 

  

 

  

 

  

Cash paid

$

27.0

$

16.6

$

11.2

$

76.6

$

55.4

Cash acquired

 

 

(0.2)

 

(1.9)

 

(3.4)

 

(1.4)

Contingent consideration

 

5.3

 

4.3

 

 

 

Total consideration transferred

$

32.3

$

20.7

$

9.3

$

73.2

$

54.0

Allocation of Consideration Transferred:

 

  

 

  

 

  

 

  

 

  

Inventories

$

2.8

$

3.0

$

$

9.7

$

10.1

Accounts receivable

 

0.8

 

1.8

 

2.4

 

5.9

 

3.7

Other current and non-current assets

 

1.1

 

0.7

 

0.8

 

1.5

 

2.0

Property, plant and equipment

 

 

 

0.1

 

2.3

 

1.5

Intangible assets:

 

  

 

  

 

  

 

  

 

  

Technology

 

7.3

 

7.0

 

4.9

 

38.1

 

15.2

Customer relationship

 

8.0

 

7.5

 

4.7

 

38.6

 

19.8

Backlog

 

1.8

 

1.1

 

 

 

2.3

Trade name

 

0.6

 

0.6

 

0.5

 

3.9

 

1.9

Goodwill

 

16.6

 

8.0

 

12.5

 

42.3

 

19.3

Deferred taxes, net

 

(3.2)

 

(4.9)

 

(2.5)

 

(19.6)

 

(9.1)

Liabilities assumed

 

(3.5)

 

(4.1)

 

(1.3)

 

(15.0)

 

(6.5)

Assumed debt

 

 

 

 

(11.3)

 

(6.2)

Redeemable noncontrolling interest

 

 

 

 

(23.2)

 

Hybrid instrument liability

 

 

 

(12.8)

 

 

Total consideration transferred

$

32.3

$

20.7

$

9.3

$

73.2

$

54.0

2017 Acquisitions  
Acquisitions  
Schedule of consideration transferred and the respective reporting segment for each acquisition

Name of Acquisition

    

Date Acquired

    

Segment

    

Consideration

    

Cash Consideration

InVivo Biotech Svs GmbH. 

January 2, 2017

BSI Life Science

$

9.1

$

9.1

Hysitron, Incorporated

January 23, 2017

 

BSI NANO

 

28.8

 

27.2

Luxendo GmbH

May 5, 2017

 

BSI NANO

 

21.9

 

18.8

XGLab S.r.l.

August 1, 2017

BSI NANO

5.5

5.5

Other

 

Various

 

BSI Life Science

 

6.0

 

5.7

 

 

  

$

71.3

$

66.3